Document Detail


The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
MedLine Citation:
PMID:  11226003     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Rituximab (Rituxan; Genentech, Inc, South San Francisco, CA and IDEC Pharmaceutical Corporation, San Diego, CA) is a monoclonal antibody that targets the CD20 antigen present in most B-cell non-Hodgkin's lymphomas. Previous studies have shown overall response rates (ORR) of approximately 50% in relapsed patients. Ibritumomab is the murine parent anti-CD20 antibody that is linked through a MX-DTPA chelator to yttrium 90 (90Y) to form the radioimmunoconjugate 90Y-ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA). A phase I study of 90Y-ibritumomab tiuxetan determined that 0.4 mCi/kg was the maximum tolerated dose, and responses were reported in 67% of all patients and in 82% of patients with low-grade non-Hodgkin's lymphoma. A separate trial randomized eligible patients to either rituximab or 90Y-ibritumomab tiuxetan. An interim analysis of the first 90 patients showed an ORR of 80% with 90Y-ibritumomab tiuxetan versus 44% with rituximab (P < .05). A subsequent trial for patients with rituximab-refractory disease showed a 46% ORR. These studies show that 90Y-ibritumomab tiuxetan is an active agent in relapsed non-Hodgkin's lymphoma and appears to have a higher ORR compared with unconjugated rituximab.
Authors:
T E Witzig
Related Documents :
8489463 - Outcome of pregnancy in patients with organic heart disease in taiwan.
18708873 - Infectious diseases in pregnancy: issues of screening, prevention, and treatment.
9854733 - Transvaginal sonographic diagnosis of short-rib polydactyly dysplasia at 13 weeks' gest...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Seminars in oncology     Volume:  27     ISSN:  0093-7754     ISO Abbreviation:  Semin. Oncol.     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2001-02-27     Completed Date:  2001-04-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0420432     Medline TA:  Semin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  74-8     Citation Subset:  IM    
Affiliation:
Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Humans
Lymphoma, B-Cell / therapy*
Pentetic Acid / analogs & derivatives*
Radioimmunotherapy / methods*
Radiotherapy Planning, Computer-Assisted
Randomized Controlled Trials as Topic
Recurrence
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/ibritumomab tiuxetan; 0/rituximab; 141849-44-7/2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid; 67-43-6/Pentetic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Principles of radioimmunotherapy for hematologists and oncologists.
Next Document:  The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.